https://www.thebodypro.com/category/first-line-hiv-treatment/tag/croi-conference-on-retroviruses-and-opportunistic-infections
First-Line HIV Treatment

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

holding hands

Scientists Report Documented Sustained HIV Remission in a 4-Year-Old Child

Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.

By Sony Salzman
TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base
Earlier Start of Antiretroviral Therapy Impacts Aging With HIV (Video) Img

Earlier Start of Antiretroviral Therapy Impacts Aging With HIV (Video)

On behalf of IFARA, executive producer Fred Schaich spoke with Seema Desai, Ph.D., Peter Hunt, M.D., and Alan Landay, Ph.D., about managing HIV in those over 50 years old.

By Barbara Jungwirth
A Tenofovir-Sparing Regimen Could Be a Safer Alternative for Starting Treatment Img

A Tenofovir-Sparing Regimen Could Be a Safer Alternative for Starting Treatment

The ACTG A5303 study at CROI 2015 was a double-blind, randomized trial that compared maraviroc (Selzentry, Celsentri), at 150 mg once daily, to tenofovir (TDF, Viread) in 259 treatment-naive patients, both arms with ritonavir (Norvir)-boosted darunav...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Fat Gains After Starting HIV Treatment Associated With High Viral Loads Img

Fat Gains After Starting HIV Treatment Associated With High Viral Loads

Having a high viral load when starting treatment was most consistently associated with body composition changes after starting antiretroviral therapy.

By Theo Smart
HIV Transmission Risk Remains During First 6 Months of Treatment Img

HIV Transmission Risk Remains During First 6 Months of Treatment

A person living with HIV can transmit the virus during the first six months of starting treatment. Researchers suggest extra prevention strategies for mixed-status couples during this period before viral suppression is achieved.

By Terri Wilder, M.S.W.
Starting HIV Treatment Early Leads to Better Health and Improved Immune Systems Img

Starting HIV Treatment Early Leads to Better Health and Improved Immune Systems

Two studies presented at CROI 2015 provided results that describe the benefits to starting HIV treatment early, in terms of time (within three months of infection) and in terms of CD4 count (greater than 350 cells).

By Project Inform
Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start Img

Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start

Researchers found that people with higher viral loads when they first start ART are more likely to have substantial body composition changes than those who start treatment with a lower viral load.

By Emily Newman for BETA
Promo Image

Raltegravir Superior to Boosted Protease Inhibitors as First-Line Treatment

U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.